Navigation Links
Phosphagenics Announces Completion of Transdermal Patch Prototypes
Date:5/29/2009

d by Phosphagenics have demonstrated that its patented technology can deliver opiates through the skin without causing any skin damage or irritation. Incorporating this technology into a patch will enable a more convenient and effective treatment that is capable of meeting the needs of pain sufferers and addresses the concerns of regulatory authorities regarding potential abuse.

In this most recent preclinical study, oxycodone concentrations produced by the patch reached approximately 160ng/ml and remained significantly elevated (p<0.01) and within therapeutic range for the duration of the four hour study. In contrast, the TPM/oxycodone gel produced peak plasma oxycodone concentrations of approximately 80ng/ml 30 minutes after application and declined from that point over the course of the trial.

"The development of our TPM patch has the potential to be a substantial commercial success for Phosphagenics," said Dr. Ogru. "Our transdermal patch should increase the amount and duration of oxycodone delivered into the systemic circulation, and could reduce potential opioid abuse, a major consideration for the FDA when reviewing possibly addictive substances such as oxycodone. In addition, our TPM skin patch should allow us to deliver other opioid based compounds, including morphine and hydromorphone, as well as other products that are targeted for delivery into the systemic circulation, including insulin. Phosphagenics has already completed a human trial that demonstrated that its TPM/insulin formulation safely delivered insulin transdermally into patients with Type 1 diabetes."

APPENDIX AND NOTES TO EDITORS

About Phosphagenics Limited

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical produc
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
2. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
3. Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy
4. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
5. Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better
6. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
7. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
8. Medivation Announces Pricing of Public Offering
9. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
10. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
11. SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2015)... Aurigene and its partner ... presenting data at the poster sessions from two ... Annual Meeting (April 18-22 in Philadelphia, ... http://photos.prnewswire.com/prnh/20130418/608115 ) , Aurigene will present ... molecule inhibitors program, which is currently in preclinical ...
(Date:4/17/2015)... 2015 Reed Technology and Information ... data management, preparation, and submission to the U.S. Food ... a new Lot Distribution Report (LDR) service for manufacturers ... compliant with the FDA’s new rule on electronic submission ... monitor the volume and timing of particular biologics introduced ...
(Date:4/17/2015)... - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF), a ... commercializes proprietary technologies and products for advanced microarray ... approval from the TSX Venture Exchange to extend ... warrants ("the Warrants") of the Company, which were ... private placement financing. Each Warrant entitles ...
(Date:4/17/2015)... , April 17, 2015  US-Australian drug discovery company, ... Memorandum of Understanding with the Feinstein Institute for ... York to collaborate with the objective ... The collaboration brings together the drug discovery ... expertise of the Feinstein Institute in neurosciences and ...
Breaking Biology Technology:Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6
... Been Filed With the FDA for the Fourth Genmab ... Under the Company,s Collaboration with Roche., COPENHAGEN, December ... Investigational New Drug application (IND) for a,Genmab antibody developed ... the FDA by Roche. Genentech and Roche are collaborating ...
... Dec. 11 The Tauri Group LLC is ... provide Systems Engineering and,Technical Assistance (SETA) support for ... Health Affairs Early Detection Division Chemical,and Biological Early ... $38 million and the period of performance is ...
... 11 PPD, Inc. (Nasdaq:,PPDI) will release its fiscal ... the market closes. The release will be available on,the ... PR Newswire., On Wednesday, January 9, 2008, at ... and audio webcast to discuss its financial guidance for,fiscal ...
Cached Biology Technology:Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3The Tauri Group LLC Awarded U.S. Department of Homeland Security Chemical and Biological Early Detection Systems Program Office Support Contract 2PPD Announces 2008 Financial Guidance Webcast and Conference Call 2
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... unique aroma signature of the durian revered as the ... the world,s foulest smelling food has uncovered several new ... ACS, Journal of Agricultural and Food Chemistry . ... food shops in the United States and elsewhere, has a ...
... in a Duke University-led study contained potentially toxic or untested chemical ... Among the chemicals detected was "Tris," a chlorinated flame ... studies. "Tris was phased out from use in ... it still showed up in 41 percent of the couch foam ...
... Toronto, ON (27 November, 2012) -- A new method of ... The discovery, which transforms aged stem cells into cells that ... to grow cardiac patches for damaged or diseased hearts from ... avoiding the threat of rejection. Stem cell therapies ...
Cached Biology News:Potentially toxic flame retardants found in many US couches 2'Fountain of youth' technique rejuvenates aging stem cells 2
Human FADD Affinity Purified Polyclonal Ab...
(3-[125I]iodotyrosyl26)Galanin (porcine), 925 kBq, 25 uCi. Category: IODINE LIGANDS....
... high-performance triple quadrupole 1200L sets the ... cost-conscious environment - incorporating the latest ... all liquid chromatography analytical needs. ... and the Transmission Quadrupole Analyzer provide ...
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: